| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner
2 companies
David V Goeddel last filed a Form 4 in May 2025, as Director, 10% Owner at TNYA. The filings on record cover 2 companies. David V Goeddel's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, David V Goeddel's trades have earned a strong insider score of 71/100 across 8 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +31.4%.
At the last filing, the largest reported position was 49,313,559 shares of TNYA. Net of sales, the TNYA filings show accumulation of 49,313,559 shares.
David V Goeddel has 13 Form 4 filings on record from November 2019 to May 2025, across 2 companies: Director, 10% Owner at Tenaya Therapeutics (TNYA), 2021–2025; Director, 10% Owner at RAPT Therapeutics (RAPT), 2019.
The 23 reported transactions were 11 open-market purchases, 8 conversions and 4 option or other derivative awards.
Counted by filing, the open-market trades come to 8 purchases worth about $72.1M and no sales.
The largest open-market purchase was 35,714,284 shares of TNYA at an average $0.70 on March 5, 2025, about $25.0M. Twelve months later TNYA was up 80%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2025 | TNYA Tenaya Therapeutics, Inc. | Director, 10% Owner | Buy | 35,714,284 | $0.70 | $24,999,998.80 | +262.6% | +7.7% | +80.1% | |
| Feb 12, 2024 | TNYA Tenaya Therapeutics, Inc. | Director, 10% Owner | Buy | 2,222,222 | $4.50 | $9,999,999.00 | +19.5% | -24.4% | -83.3% | |
| Mar 10, 2023 | TNYA Tenaya Therapeutics, Inc. | Director, 10% Owner | Buy | 6,779 | $2.60 | $17,595.57 | - | +183.5% | +145.2% | |
| Feb 8, 2023 | TNYA Tenaya Therapeutics, Inc. | Director, 10% Owner | Buy | 1,500,000 | $2.60 | $3,900,000.00 | +15.2% | +136.6% | +85.9% | |
| Jan 19, 2023 | TNYA Tenaya Therapeutics, Inc. | Director, 10% Owner | Buy | 69,739 | $2.50 | $174,201.05 | +0.7% | +40.6% | +50.2% | |
| Jan 18, 2023 | TNYA Tenaya Therapeutics, Inc. | Director, 10% Owner | Buy | 185,151 | $2.51 | $464,827.06 | +1.9% | +21.4% | +26.6% | |
| Nov 21, 2022 | TNYA Tenaya Therapeutics, Inc. | Director, 10% Owner | Buy | 9,615,384 | $2.60 | $24,999,998.40 | New | +36.9% | -22.3% | |
| Nov 4, 2019 | RAPT Rapt Therapeutics, Inc. | Director, 10% Owner | Buy | 625,000 | $12.00 | $7,500,000.00 | +14.3% | - | - |